Full-Service CDMO

Commercial-Scale
Peptide & Oligo
CDMO Manufacturing
Solutions

Integrated CDMO services built for true commercial readiness — from early development through multi-ton GMP production.

Our Services

Sinopep Biopharma is a trusted full-service Peptide and Oligo CDMO offering comprehensive end-to-end CMC development and commercial manufacturing solutions for global partners.

Peptide CDMO Services CMC Development Commercial

Peptide CDMO Services

Comprehensive GMP peptide manufacturing services designed to support projects across all stages of development through to full commercialization.

Peptide CDMO Services CMC Development Commercial

GMP Oligo Services

We provide end-to-end oligonucleotide manufacturing services — from research-grade to clinical-grade — supporting clients across all phases of development.

Peptide CDMO Services CMC Development Commercial

FTE Services

Our FTE (Full-Time Equivalent) agreements offer a unique approach for long-term peptide and oligonucleotide manufacturing projects involving multiple targets.

Peptide CDMO Services CMC Development Commercial

Discovery Services

Sinopep's research-grade peptide and oligonucleotide synthesis services are designed to support our clients' discovery efforts. Chemical design services available.

Peptide CDMO Services CMC Development Commercial

Generic APIs

Sinopep specializes in the development and manufacturing of high-quality peptide, oligonucleotide, and small molecule active pharmaceutical ingredients (APIs).

Peptide CDMO Services CMC Development Commercial

Formulation

Finished Dosage Form (FDF) Formulation Services. Oral Solid Dosage Form and Lyophilized Powder Injections. Sterile and Non-sterile preparations also supported.

About US

Commercial Supply

Sinopep-Allsino Biopharmaceutical Co., Ltd. is a leading worldwide commercial API supplier and full-service CDMO, delivering large-scale GMP manufacturing for peptides, oligonucleotides, and small molecules to support global biopharma partners from development through commercial supply. We provide established peptide capacity of 20–30 metric tons annually, proven commercial-scale production for small molecule generics and NCEs, and our new large-scale GMP oligonucleotide facility in Jiangsu Lianyungang capable of thousands of kilograms per year—including ASOs, siRNA, and advanced conjugates (GalNAc, AOCs, lipid-based, POCs). With FDA-inspected facilities, strong regulatory expertise, and seamless end-to-end capabilities, Sinopep ensures reliable, high-quality, and cost-effective commercial API supply for innovative therapeutics worldwide.

Years Experience

Employees

Capacity (MT/yr)

GMP Faclities

Upcoming Events

Sinopep would love to meet you at our next event!

Sinopep Exhibiting at Boulder Peptide Symposium in Napa Valley
28
September
September 28 - October 01, 2026
Silverado Resort in Napa, CA | Booth #11
Napa CA
Exhibitions
Sinopep at CPHI Milan
06
October
October 6 - October 08, 2026
Fiera Milano | Booth #4H7
Rho Milano
Exhibitions

Sinopep News

Latest Press Releases from Sinopep

Sinopep attends DCAT week

2026 DCAT Week with Sinopep

Reflecting on an energizing few days at DCAT 2026 in New York, with great conversations across peptides, oligonucleotides, and small molecules and genuine appreciation for everyone who connected with the Sinopep team.

read more...
SInopep exhibition at CPHI India

Exhibition at CPHI India 2025

Show more10:11 AMClaude responded: Reflecting on a productive and energizing week at CPHI India 2025 in Delhi, with strong engagement across peptide and oligonucleotide development, manufacturin…Reflecting on a productive and energizing week at CPHI India 2025 in Delhi, with strong engagement across peptide and oligonucleotide development, manufacturing, and generics partnerships.

read more...

Video Introduction

Explore Our Commercial-Scale Facility

GMP Peptide Manufacturing Video

Large-scale automated peptide synthesis

Sinopep is a trusted Contract Development and Manufacturing Organization (CDMO) specializing in end-to-end CMC development and cGMP manufacturing of peptide and oligonucleotide APIs for new chemical entities (NCEs). Since 2009, we’ve supported global pharmaceutical innovators across all phases—from early development to commercialization. With a strong regulatory track record, including four successful U.S. FDA inspections, Sinopep adheres strictly to FDA and ICH guidelines. Our integrated services span process development, analytical method development and validation, stability studies, and regulatory support for IND and NDA filings worldwide.

New Heights

Start your Journey with Sinopep

Comprehensive GMP manufacturing and formulation capabilities to support your projects across all stages—from early discovery and late-phase development through to full commercialization.